Myocardial bridging as a common phenotype of hypertrophic cardiomyopathy has no effect on prognosis
Related Experiment Video
Updated: May 5, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Tao Tian1, Yi-Lu Wang, Ji-Zheng Wang
1Departments of Cardiology (TT, Y-LW, B-ZY, RT-H, X-LZ, LS), Sino-German Laboratory for Molecular Medicine (J-ZW, KS, W-LZ, R-TH), and Hypertension Center (RT-H, X-LZ, LS), State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; and Department of Cardiology (LZ, HS), First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, China.
Insights
Myocardial bridging is common in hypertrophic cardiomyopathy (HCM) but does not predict adverse outcomes like death or heart failure. This finding clarifies the prognostic significance of myocardial bridging in HCM patients.
Area of Science:
- Cardiology
- Cardiovascular Research
- Medical Diagnostics
Background:
- Prognostic significance of myocardial bridging in hypertrophic cardiomyopathy (HCM) is debated.
- This study aimed to clarify the impact of myocardial bridging on HCM patient prognosis.
Purpose of the Study:
- To investigate the association between myocardial bridging and clinical outcomes in patients with hypertrophic cardiomyopathy.
- To determine if myocardial bridging predicts adverse events in HCM.
Main Methods:
- Retrospective analysis of 298 adult HCM patients (1999-2011).
- Myocardial bridging assessed via coronary angiography.
- Follow-up data collected through interviews and questionnaires.
Main Results:
- Myocardial bridging identified in 11% of patients, most commonly in the left anterior descending artery.
- Patients with bridging were younger.
- No significant association found between myocardial bridging and all-cause death, cardiovascular death, sudden cardiac death, or heart failure deterioration.
Conclusions:
- Myocardial bridging is a frequent finding in hypertrophic cardiomyopathy.
- Myocardial bridging is not a predictor of adverse clinical outcomes in HCM patients.
Background:
The prognostic significance of myocardial bridging in hypertrophic cardiomyopathy (HCM) remains controversial. This investigation sought to evaluate the impact of myocardial bridging on prognosis of patients with HCM.
Methods:
A total of 298 adult patients (73% male, mean age, 53 ± 12 years) with HCM were retrospectively enrolled at Fuwai Hospital from 1999 to 2011. Myocardial bridging was evaluated by coronary angiography. Follow-up data were collected by telephone interviews and mailed questionnaires.
Results:
Thirty-four (11%, 34/298) patients were determined with myocardial bridging and the middle of left anterior descending artery was the most frequently involved segment (77%, 26/34). Patients with myocardial bridging were younger than those without bridging (48 ± 9 versus 54 ± 12 years, P = 0.001). During the follow-up of 4.2 ± 2.3 years (range, 0.7-12.2 years), the presence of myocardial bridging was not evidently associated with increased risk for all-cause death (P = 0.54), cardiovascular death (P = 0.60), sudden cardiac death (P = 0.53) and deterioration of heart failure (P = 0.84).
Conclusions:
Myocardial bridging was a relatively common morphological component of HCM but not a predictor for adverse clinical outcomes.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Myocarditis I: Introduction

